PD-(L)1抑制剂单药或联合铂类双药化疗一线治疗PD-L1高表达非鳞状非小细胞肺癌的真实世界疗效
本研究利用真实世界去标识数据库,回顾性比较PD-L1高表达(≥50%)转移性非鳞状非小细胞肺癌患者一线接受PD-(L)1抑制剂单药(351例)或联合铂类化疗(169例)的生存结局。中位随访19.9个月(联合组)对23.5个月(单药组),两组中位总生存和无进展生存均无显著差异。仅在从不吸烟亚组(n=50)中联合化疗显示总生存和无进展生存改善。
要点
- PD-L1高表达非鳞状非小细胞肺癌一线免疫单药与免疫联合化疗的总生存和无进展生存无显著差异。
- 从不吸烟亚组(n=50)中联合化疗较单药改善总生存(HR=0.25)和无进展生存(HR=0.40)。
- 除从不吸烟亚组外,一线免疫治疗中省略化疗似乎不影响生存结局。
核心结论
- 除从不吸烟患者亚组外,在PD-L1高表达非鳞状非小细胞肺癌患者中,一线免疫治疗省略化疗似乎不影响生存结局。
研究设计与样本
- 回顾性队列研究,使用真实世界去标识数据库。
- 纳入2016年10月24日至2019年2月28日期间开始一线PD-(L)1抑制剂单药或联合铂类化疗的转移性非鳞状非小细胞肺癌且PD-L1高表达(≥50%)患者,随访至2020年2月28日。
- 采用Kaplan-Meier法比较总生存和真实世界无进展生存,采用逆概率治疗加权法调整基线关键预后特征差异后计算调整风险比(aHR)。
主要发现
- 单药组患者年龄更大,且初诊IV期疾病比例低于联合化疗组。
- 联合化疗组中位随访19.9个月,单药组中位随访23.5个月。
- 中位总生存:联合化疗组21.0个月 vs 单药组22.1个月,aHR=1.03,95%CI 0.77-1.39,P=0.83。
- 中位真实世界无进展生存:联合化疗组10.8个月 vs 单药组11.5个月,aHR=1.04,95%CI 0.78-1.37,P=0.81。
- 从不吸烟亚组(n=50)中,联合化疗较单药显著改善总生存(HR=0.25,95%CI 0.07-0.83,交互P=0.02)和无进展生存(HR=0.40,95%CI 0.17-0.95,交互P=0.04)。
关键数值与推荐
- PD-L1高表达定义为肿瘤比例评分(TPS)或肿瘤细胞(TC)≥50%。
- 主要比较指标为总生存和真实世界无进展生存。
临床怎么用
- 作者结论指出,除从不吸烟患者亚组外,一线免疫治疗省略化疗似乎不影响PD-L1高表达非鳞状非小细胞肺癌患者的生存结局。
局限性
- 从不吸烟亚组样本量小(n=50)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-programmed cell death protein (death-ligand) 1 [PD-(L)1] therapy alone [cancer immunotherapy (CIT)-mono] or combined with platinum-based chemotherapy (CIT-chemo) is used as the first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC). Our study compared clinical outcomes with CIT-mono versus CIT-chemo in the specific clinical scenario of non-squamous (Nsq)-NSCLC with a high PD-L1 expression of ≥50% [tumor proportion score (TPS) or tumor cells (TC)]. METHODS: This was a retrospective cohort study using a real-world de-identified database. Patients with metastatic Nsq-NSCLC with high PD-L1 expression initiating first-line CIT-mono or CIT-chemo between 24 October 2016 and 28 February 2019 were followed up until 28 February 2020. We compared overall survival (OS) and real-world progression-free survival (rwPFS) using the Kaplan-Meier methodology. Hazard ratios (HRs) were adjusted (aHR) for differences in baseline key prognostic characteristics using the inverse probability of treatment weighting methodology. RESULTS: Patients with PD-L1-high Nsq-NSCLC treated with CIT-mono (n = 351) were older and less often presented with de novo stage IV disease than patients treated with CIT-chemo (n = 169). With a median follow-up of 19.9 months for CIT-chemo versus 23.5 months for CIT-mono, median OS and rwPFS did not differ between the two groups [median OS: CIT-chemo, 21.0 months versus CIT-mono, 22.1 months, aHR = 1.03, 95% confidence interval (CI) 0.77-1.39, P = 0.83; median rwPFS: CIT-chemo, 10.8 months versus CIT-mono, 11.5 months, aHR = 1.04, 95% CI 0.78-1.37, P = 0.81]. CIT-chemo showed significant and meaningful improvement in OS and rwPFS versus CIT-mono only in the never-smoker subgroup, albeit among a small sample of patients (n = 50; OS HR = 0.25, 95% CI 0.07-0.83, interaction P = 0.02; rwPFS HR = 0.40, 95% CI 0.17-0.95, interaction P = 0.04). CONCLUSION: Except in the subgroup of never-smoker patients, sparing the chemotherapy in first-line CIT treatment does not appear to impact survival outcomes in Nsq-NSCLC patients with high PD-L1 expression.
引用
- Pérol M, Felip E, Dafni U, et al. Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data. Ann Oncol. 2022. PMID: 35218887. doi:10.1016/j.annonc.2022.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。